Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Answer: July Coding Challenge

Staff  |  Issue: July 2013  |  July 1, 2013

Take the challenge…

Answer: 96375, J1200 x1, 96413, 96415×1, J1745 –EJ x 20, Diagnosis 714.0

Infliximab is considered a chemotherapy infusion. Even though the push for the methylprednisolone was done first, it should be coded as a subsequent code. As per CPT coding guidelines, only one initial code may be used within the drug administration family. It would not matter that the 96375 was done first. It is permissible to code the 96413 as the initial code because this is the main procedure. CPT 96413 is used to code for the first hour of a chemotherapy infusion, and 96415 is used to code each additional hour of a chemotherapy infusion, up to eight hours.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Because the patient’s infliximab was infused over two hours and 10 minutes, it is coded 96413 and 96415×1. The time starts for the infusion when the actual medication starts, not when the IV port is inserted. HCPCS code J1745 is the drug code for infliximab 10 mg. Because the patient received 200 mg of infliximab, the correct way to code this treatment is J1745x20 (20×10=200 mg). The EJ modifier should be added to the drug code for subsequent claims for a defined course of therapy (e.g., EPO, sodium hyaluronate, and infliximab). The EJ modifier is an informational modifier except for the Medicare carrier Novitas Solutions, where it is always required to identify the subsequent doses of the above medications.

Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodinginfliximab

Related Articles

    New HCPCS Modifiers Replace -59 on January 1, 2015

    December 1, 2014

    Referred to as -X modifiers, they are designed to define specific subsets of -59 modifier

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

    Coding Corner Answer: A Quiz on Modifiers

    February 18, 2019

    Take the challenge. 1. A—Modifier -25 is defined as a significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service. It is to be placed on the E/M visit only because it attests to the payer there is…

    Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier

    April 20, 2017

    Take the challenge. CPT: 99214-25, 96413, 96375, 96361-59, J1745 x 4 J1745 JW* x 36, J1200 x1 ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEICD-10: M45.09, T50.995A, R06.02, E66.3, Z68.2 Rationale Modifier 25 is appropriate to use because it indicates the patient received a significant, separately identifiable E/M service on the same day as the infliximab infusion. This…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences